Spots Global Cancer Trial Database for dabrafenib
Every month we try and update this database with for dabrafenib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations | NCT05876806 | Cancer | Dabrafenib Trametinib | 19 Years - | Seoul St. Mary's Hospital | |
| Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors | NCT05868629 | Rare Unresectab... | Non-investigati... | 6 Years - | Novartis | |
| Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | NCT02097225 | BRAF V600E Muta... BRAF V600K Muta... Metastatic Mali... Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable So... | Dabrafenib Laboratory Biom... Onalespib Pharmacological... Trametinib | 18 Years - | National Cancer Institute (NCI) | |
| PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer | NCT04544111 | Thyroid Cancer Thyroid Cancer,... Papillary Thyro... Follicular Thyr... Hurthle Cell Tu... Poorly Differen... Hurthle Cell Th... | Trametinib Dabrafenib PDR001 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)" | NCT05299580 | Melanoma | dabrafenib Trametinib | 18 Years - | Fondazione Melanoma Onlus | |
| Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain | NCT02039947 | Melanoma and Br... | Dabrafenib Trametinib | 18 Years - | Novartis | |
| Study of the Variations of Albumin Level for Patients With Unresecable Stage IIIc or Stage IV Melanoma Treated by Anti BRAF and Anti MEK | NCT03553329 | Unresecable Sta... | dabrafenib | 18 Years - 100 Years | Poitiers University Hospital | |
| Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma | NCT02910700 | Metastatic Mali... Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me... | Binimetinib Dabrafenib Encorafenib Laboratory Biom... Nivolumab Pharmacological... Trametinib | 18 Years - | M.D. Anderson Cancer Center | |
| Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma | NCT04310397 | Pathologic Stag... Pathologic Stag... Pathologic Stag... | Dabrafenib Spartalizumab Therapeutic Con... Trametinib | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | NCT02684058 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Ipon... | Dabrafenib trametinib Carboplatin Vincristine | 12 Months - 17 Years | Novartis | |
| Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma | NCT05525273 | Craniopharyngio... | Oral dabrafenib... | 18 Years - | Skane University Hospital | |
| Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients | NCT02296996 | Malignant Melan... | Dabrafenib + Tr... | 18 Years - | Universitair Ziekenhuis Brussel | |
| A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects | NCT01677741 | Neoplasms, Brai... | Dabrafenib | 12 Months - 17 Years | Novartis | |
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma | NCT01989585 | Clinical Stage ... Clinical Stage ... Malignant Solid... Metastatic Mela... Unresectable Me... | Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Echocardiograph... Laboratory Biom... Magnetic Resona... Multigated Acqu... Navitoclax Pharmacological... Trametinib | 18 Years - | National Cancer Institute (NCI) | |
| E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS) | NCT03332589 | Malignant Melan... Brain Metastase... | E6201 E6201 plus dabr... | 18 Years - | Spirita Oncology, LLC | |
| Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer | NCT04739566 | Thyroid Gland A... | Dabrafenib Trametinib | 18 Years - | Saint Petersburg State University, Russia | |
| A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma | NCT03091257 | Multiple Myelom... | Dabrafenib Trametinib | 18 Years - | Massachusetts General Hospital | |
| Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam | NCT02082665 | Cancer | Rosuvastatin10 ... Midazolam 3 mg ... Dabrafenib 75 m... | 18 Years - 65 Years | GlaxoSmithKline | |
| Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases | NCT02974803 | Melanoma Brain Metastase... | Dabrafenib Trametinib | 18 Years - | Canadian Cancer Trials Group | |
| Pediatric Long-Term Follow-up and Rollover Study | NCT03975829 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Lipo... Neurofibromatos... | dabrafenib trametinib | 1 Year - | Novartis | |
| Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection | NCT04666272 | Melanoma | dabrafenib trametinib | 18 Years - 100 Years | Novartis | |
| Pediatric Long-Term Follow-up and Rollover Study | NCT03975829 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Lipo... Neurofibromatos... | dabrafenib trametinib | 1 Year - | Novartis | |
| Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes | NCT03551626 | Malignant Melan... | Dabrafenib Trametinib | 18 Years - | Novartis | |
| Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part) | NCT01928940 | Solid Tumours | dabrafenib trametinib | 20 Years - | GlaxoSmithKline | |
| Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma | NCT03754179 | Melanoma | Dabrafenib Trametinib Hydroxychloroqu... | 18 Years - | Universitair Ziekenhuis Brussel | |
| MCS110 With BRAF/MEK Inhibition in Patients With Melanoma | NCT03455764 | Melanoma | MCS110 Dabrafenib Trametinib | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma | NCT02967692 | Melanoma | Spartalizumab Placebo Dabrafenib Trametinib | 18 Years - | Novartis | |
| A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer | NCT04294160 | BRAF V600 Color... | Dabrafenib LTT462 Trametinib LXH254 TNO155 Spartalizumab Tislelizumab | 18 Years - | Novartis | |
| Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations | NCT05876806 | Cancer | Dabrafenib Trametinib | 19 Years - | Seoul St. Mary's Hospital | |
| A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) | NCT02130466 | Melanoma Solid Tumors | Pembrolizumab Dabrafenib Trametinib Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer | NCT04507919 | Small Cell Lung... | Dabrafenib Trametininb | 18 Years - 99 Years | Novartis | |
| A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib | NCT02382549 | Melanoma | BRAF inhibitor 6MHP MEK inhibitor | 18 Years - | University of Virginia | |
| Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib | NCT02357732 | Metastatic Mela... | Nivolumab Trametinib Dabrafenib | 18 Years - | University of Pittsburgh | |
| A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects | NCT01677741 | Neoplasms, Brai... | Dabrafenib | 12 Months - 17 Years | Novartis | |
| Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery | NCT01947023 | Metastatic Thyr... Unresectable Th... | Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Dabrafenib Mesy... Echocardiograph... Lapatinib Lapatinib Ditos... Magnetic Resona... Multigated Acqu... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration | NCT04201457 | Low Grade Gliom... High Grade Glio... Low Grade Gliom... | Dabrafenib Trametinib Hydroxychloroqu... | 1 Year - 30 Years | Pediatric Brain Tumor Consortium | |
| Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets | NCT01721603 | BRAFV600E Melan... | Dabrafenib Gamma Knife Rad... Trametinib | 18 Years - | University of California, San Francisco | |
| A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors | NCT01954043 | Cancer | Dabrafenib 150 ... Rabeprazole 40 ... Rifampin 600 mg... | 18 Years - | GlaxoSmithKline | |
| Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation | NCT02231775 | Stage IIIB Cuta... Stage IIIC Cuta... | Dabrafenib Laboratory Biom... Therapeutic Con... Trametinib | 18 Years - | M.D. Anderson Cancer Center | |
| Study of the Variations of Albumin Level for Patients With Unresecable Stage IIIc or Stage IV Melanoma Treated by Anti BRAF and Anti MEK | NCT03553329 | Unresecable Sta... | dabrafenib | 18 Years - 100 Years | Poitiers University Hospital | |
| Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma | NCT01767454 | Solid Tumours | Dabrafenib Trametinib Ipilimumab | 18 Years - | GlaxoSmithKline | |
| Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer | NCT03975231 | BRAF NP_004324.... BRAF V600K Muta... Thyroid Gland A... | Dabrafenib Intensity-Modul... Trametinib | 18 Years - | City of Hope Medical Center | |
| A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC | NCT04452877 | Carcinoma, Non-... | Dabrafenib Trametinib | 18 Years - | Novartis | |
| Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | NCT02684058 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Ipon... | Dabrafenib trametinib Carboplatin Vincristine | 12 Months - 17 Years | Novartis | |
| Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer | NCT03244956 | Metastatic Radi... | Trametinib Dabrafenib 131I rhTSH | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma | NCT02447939 | Melanoma | Dabrafenib Trametinib | 18 Years - | GlaxoSmithKline | |
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection | NCT04666272 | Melanoma | dabrafenib trametinib | 18 Years - 100 Years | Novartis | |
| A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib | NCT02382549 | Melanoma | BRAF inhibitor 6MHP MEK inhibitor | 18 Years - | University of Virginia | |
| Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC | NCT02672358 | Non-Small-Cell ... | Dabrafenib Trametinib | 18 Years - | Novartis | |
| Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma | NCT02083354 | Cancer Melanoma | Dabrafenib Trametinib | 18 Years - | Novartis | |
| A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors | NCT01954043 | Cancer | Dabrafenib 150 ... Rabeprazole 40 ... Rifampin 600 mg... | 18 Years - | GlaxoSmithKline | |
| Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients | NCT02625337 | Metastatic Mela... | Pembrolizumab Dabrafenib Trametinib Biopsy Blood taking | 18 Years - | The Netherlands Cancer Institute | |
| Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery | NCT01947023 | Metastatic Thyr... Unresectable Th... | Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Dabrafenib Mesy... Echocardiograph... Lapatinib Lapatinib Ditos... Magnetic Resona... Multigated Acqu... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery | NCT01701037 | Recurrent Melan... Stage IIB Melan... Stage IIC Melan... Stage IIIA Mela... Stage IIIB Mela... Stage IIIC Mela... Stage IV Melano... | dabrafenib trametinib laboratory biom... | 18 Years - 90 Years | Vanderbilt-Ingram Cancer Center | |
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma | NCT06264778 | Ameloblastoma | Dabrafenib | 18 Years - 65 Years | Shandong University | |
| Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer | NCT04940052 | Differentiated ... | Dabrafenib Trametinib Trametinib plac... Dabrafenib plac... | 18 Years - | Novartis | |
| Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets | NCT01721603 | BRAFV600E Melan... | Dabrafenib Gamma Knife Rad... Trametinib | 18 Years - | University of California, San Francisco | |
| Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone | NCT02027961 | Melanoma | Durvalumab Dabrafenib Trametinib | 18 Years - | MedImmune LLC | |
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | NCT01726738 | Stage III Melan... Stage IV Melano... Unresectable Me... BRAF Mutant Mel... | BRAF inhibitor ... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma | NCT02447939 | Melanoma | Dabrafenib Trametinib | 18 Years - | GlaxoSmithKline | |
| Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone | NCT02027961 | Melanoma | Durvalumab Dabrafenib Trametinib | 18 Years - | MedImmune LLC | |
| Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma | NCT06264778 | Ameloblastoma | Dabrafenib | 18 Years - 65 Years | Shandong University | |
| Dabrafenib + Trametinib + PDR001 In Colorectal Cancer | NCT03668431 | Metastatic Colo... | Dabrafenib Trametinib PDR001 | 18 Years - | Massachusetts General Hospital | |
| Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery | NCT01940809 | BRAF V600E Muta... BRAF V600K Muta... Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... | Dabrafenib Ipilimumab Laboratory Biom... Nivolumab Trametinib | 18 Years - | National Cancer Institute (NCI) | |
| PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer | NCT04544111 | Thyroid Cancer Thyroid Cancer,... Papillary Thyro... Follicular Thyr... Hurthle Cell Tu... Poorly Differen... Hurthle Cell Th... | Trametinib Dabrafenib PDR001 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation | NCT02231775 | Stage IIIB Cuta... Stage IIIC Cuta... | Dabrafenib Laboratory Biom... Therapeutic Con... Trametinib | 18 Years - | M.D. Anderson Cancer Center | |
| Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma | NCT03352947 | Melanoma | Dabrafenib Trametinib | 18 Years - | Cambridge University Hospitals NHS Foundation Trust | |
| Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US | NCT05260684 | Melanoma | Encorafenib Binimetinib Vemurafenib Cobimetinib Dabrafenib Trametinib | 18 Years - | Pfizer | |
| Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma | NCT04903119 | Metastatic Mela... BRAF Gene Mutat... | Nilotinib 100mg Nilotinib 200mg Nilotinib 300mg Nilotinib 400mg Dabrafenib Trametinib | 18 Years - | University of Kentucky | |
| Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma. | NCT04961619 | Melanoma | dabrafenib trametinib | 18 Years - | Novartis | |
| Pediatric Long-Term Follow-up and Rollover Study | NCT03975829 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Lipo... Neurofibromatos... | dabrafenib trametinib | 1 Year - | Novartis | |
| Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study | NCT02052193 | Metastatic Mela... | Dabrafenib Vemurafenib | 18 Years - | University Hospital Tuebingen | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | NCT02465060 | Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ... | Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib | 18 Years - | National Cancer Institute (NCI) | |
| Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib | NCT05988697 | NSCLC BRAF V600E Muta... Advanced Cancer Stage IIIB NSCL... Stage IV NSCLC | Combind asprin ... | 18 Years - 75 Years | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
| E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS) | NCT03332589 | Malignant Melan... Brain Metastase... | E6201 E6201 plus dabr... | 18 Years - | Spirita Oncology, LLC | |
| Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma | NCT04903119 | Metastatic Mela... BRAF Gene Mutat... | Nilotinib 100mg Nilotinib 200mg Nilotinib 300mg Nilotinib 400mg Dabrafenib Trametinib | 18 Years - | University of Kentucky | |
| Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma | NCT03149029 | Metastatic Mela... | Pembrolizumab Dabrafenib Trametinib | 18 Years - | Massachusetts General Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
